Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

722
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
722
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

491
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
491
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis.

European heart journal·2026
Same author

Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF Trial.

Journal of the American College of Cardiology·2026
Same author

iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025.

Heart views : the official journal of the Gulf Heart Association·2026
Same author

Comparative Prognosis of Chagas and Other Cardiomyopathies.

Journal of the American College of Cardiology·2026
Same author

Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.

JACC. Heart failure·2026
Same author

Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF.

European journal of heart failure·2026
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Mar 3, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

心不全

Marco Metra1, John R Teerlink2

  • 1Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Lancet (London, England)
|May 3, 2017
PubMed
まとめ
この要約は機械生成です。

心不全の治療は改善されていて 血管新生素受容体ネプリリン阻害剤 (RNAI) のような新薬が有望です しかし,エジェクション分子が保存された心不全の効果的な治療法は,未満たされた臨床的ニーズを強調しています.

さらに関連する動画

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

関連する実験動画

Last Updated: Mar 3, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

科学分野:

  • 心臓病科
  • 内科 医学

背景:

  • 心不全 (HF) は,人口の高齢化と急性心血管疾患の管理の改善により増加する世界的な健康問題です.
  • ACE阻害薬,ARB,β阻害薬,RNAIなど,エジェクション分子が減少した心不全 (HFrEF) に対する治療法が存在しますが,特にエジェクション分子が保存された心不全 (HFpEF) に対して,重要な満たされていない需要が残っています.

研究 の 目的:

  • 心不全の現在の治療戦略を見直し,進歩と残る課題に焦点を当てます.
  • ARNIや左心室補助器 (LVAD) のような治療法の進化する役割を強調する.
  • HFpEFの限られた治療法と新しい治療方法の必要性について議論する.

主な方法:

  • 心不全の流行病学,病理生理学,治療効果に関する現在の文献のレビュー.
  • 薬理学的およびデバイスベースの治療のためのガイドラインの勧告の分析.
  • HFrEFとHFpEFの新薬メカニズムに関する進行中の研究の検討

主要な成果:

  • アンジオテンシン受容体ネプリシン阻害剤 (RNAI) は,エナラプリルと比較して改善された結果を示し,HFrEFでの使用をガイドラインに推奨しています.
  • 左心室補助器 (LVAD) は,安全性が向上したため,重度のHFでますます使用されています.
  • スピロノラクトンに対するいくつかの証拠にもかかわらず,HFpEFに対する決定的な治療法はありません.

結論:

  • ARNIやLVADを含むHFrEF治療の進歩は,患者のアウトカムを改善していますが,HFpEFは治療上の課題です.
  • HFrEFとHFpEFの両方の満たされていないニーズに対処するために,心臓のミオシン活性化剤を含む新しい薬の開発は不可欠です.
  • 心不全に苦しんでいる人数の増加に対して 効果的な治療法を開発するために 継続的な研究が不可欠です